<DOC>
	<DOC>NCT00104182</DOC>
	<brief_summary>This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes for at least 12 months Currently treated with Oral Antidiabetic Drugs BMI lesser than or equal to 40 kg/m2 HbA1c greater than or equal 7.5 and lesser than or equal to 11% Proliferative retinopathy or maculopathy Recurrent major hypoglycaemia uncontrolled hypertension or any disease or condition (such as renal, hepatic or cardiac) that according to the judgement of the Investigator makes the subject unsuitable for participation in the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>